Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Severe pain Clinical criteria: The treatment must be for short term therapy of acute severe pain, AND Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; OR Patient must be unable to use non-opioid analgesics due to contraindications or intolerance. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife who is sharing the post-operative care of the patient with a medical practitioner.
Chronic severe pain Clinical criteria: Treatment Phase: Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months The condition must require daily, continuous, long term opioid treatment, AND Patient must have cancer pain; OR Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics; OR Patient must be unable to use non-opioid or other opioid analgesics due to contraindications or intolerance. Authorities for increased maximum quantities and/or repeats under this restriction must only be considered for chronic severe disabling pain where the total duration of non-PBS and PBS opioid analgesic treatment is less than 12 months. Authority requests extending treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia. Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
“Tramadol is a centrally-acting synthetic analgesic of the aminocyclohexanol group with opioid- like effects.”
“In young adults, the half-life of tramadol is 5 to 7 hours and the half-life of M1 is 6 to 8 hours.”
“Production of M1 is dependent on the CYP2D6 isoenzyme of cytochrome P450. N -demethylation is catalysed by the CYP3A4 isoenzyme of cytochrome P450.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.